11th World Conference on Lung Cancer of the International Association for the Study of Lung Cancer (IASLC). Barcelona, Spain July 3–6, 2005

Abstracts of the 11th World Conference on Lung Cancer. Lung Cancer 2005;49(suppl).Google Scholar

Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513–20.PubMedCrossRefGoogle Scholar

Chou T-Y, Chiu Ch-H, Li L-H, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res. 2005;11:3750–7.PubMedCrossRefGoogle Scholar

Han S-W, Kim T-Y, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005;23:2493–501.PubMedCrossRefGoogle Scholar

Cortes-Funes H, Gómez C, Rosell R, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small cell lung cancer patients. Ann Oncol. 2005;16:1081–6.PubMedCrossRefGoogle Scholar

Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res. 2005;11:5878–85.PubMedCrossRefGoogle Scholar